UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 7.

Rothschild, S I; Zippelius, A; Prince, S Savic; Gonzalez, M; Weder, W; Xyrafas, A; Rusterholz, C; Pless, M (2016). 129TiP: SAKK 16/14 - anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC): a multicenter single-arm phase II trial. Journal of Thoracic Oncology, 11(4 Suppl):S112.

Iselin, K C; Marti, P; Pless, M (2016). Hydroxychloroquine-Induced Retinal Toxicity. Klinische Monatsblätter für Augenheilkunde, 233(4):514-516.

Hanson, J V; Lukas, S C; Pless, M; Schippling, S (2016). Optical Coherence Tomography in Multiple Sclerosis. Seminars in Neurology, 36(2):177-184.

Joerger, M; Baty, F; Früh, M; Droege, C; Stahel, R A; Betticher, D C; von Moos, R; Ochsenbein, A; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, D; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer, 85(2):306-313.

Zappa, F; Droege, C; Betticher, D; von Moos, R; Bubendorf, L; Ochsenbein, A; Gautschi, O; Oppliger Leibundgut, E; Froesch, P; Stahel, R; Hess, T; Rauch, D; Schmid, P; Mayer, M; Crowe, S; Brauchli, P; Ribi, K; Pless, M (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3):239-244.

Stupp, R; Mayer, M; Kann, R; Weder, W; Zouhair, A; Betticher, D C; Roth, A D; Stahel, R A; Majno, S; Peters, S; Jost, L; Furrer, M; Thierstein, S; Schmid, R A; Hsu-Schmitz, S F; Mirimanoff, R O; Ris, H B; Pless, M (2009). Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncology, 10(8):785-793.

D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2008). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of Oncology, 19(4):739-745.

This list was generated on Thu Jul 27 13:44:22 2017 CEST.